Popular Articles

E Coli Confirmed In Nestlç© Toll House Cookie Dough Says FDA
The US Food and Drug Administration (FDA) said yesterday, June 29, that it had found E. coli O157:H7 in a sample of prepackaged Nestlç© Toll
generic viagra online
Merck Serono Initiates Phase III Study Of Stimuvax In Breast Cancer
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the initiation of its global Phase III clinical study of the therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. The STRIDEa study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study. The STRIDE study will be supervised by an expert Steering Committee and is sponsored by Merck Serono, which is leading the development of Stimuvax.
News of the day
Actual Imaging Use Far Below President's Recommend 95 Percent Utilization Rate For Medicare
The amount of time imaging equipment is in use in outpatient settings does not approach use rates President Obama and the Medicare Payment Advisory Commission (MedPAC) recommend Medicare utilize to calculate reimbursement for imaging, according to data recently collected by the Radiology Business Management Association (RBMA), a national association of business professionals in radiology.
Public Health

New Study Uncovers Mode Of Action Of Enzyme Linked With Several Types Of Cancer

Scientists at the Institute for Research in Immunology and Cancer (IRIC) of the Universitç© de Montrç©al have discovered a key mechanism used by cells to efficiently distribute chromosomes to new cells during cell multiplication. Published in the journal Molecular Cell, the study is the first to demonstrate that this mechanism relies on the polo kinase, an enzyme implicated in several cancers. Inhibiting this mechanism could be key to developing effective therapies to treat cancer. Each human cell contains, in its nucleus, all the coding instructions necessary to direct the cell"s activities. A complete set of those instructions is referred to as a genome. Cancer cells are capable of altering their genome in order to promote uncontrolled growth. "Cancer cells achieve this by gaining or losing specific chromosomes, or by inducing structural defects in their genome," explains Damien D"Amours, Principal Investigator at IRIC and director of the study, "We discovered that the polo kinase, overexpressed in a broad range of human tumours, tells the chromosomes exactly when to condense during cell division." Misregulation of the polo kinase is associated with cancers, thereby suggesting a link between defects in chromosome condensation and the formation of tumours. "Pharmaceutical companies and independent researchers are already working on the development of new cancer drugs to inhibit the activity of the polo kinase," points out Damien D"Amours, "Understanding this enzyme"s mode of action should enable us to control it. Such knowledge may reveal itself to be key in developing effective therapies to treat cancer." In a preview article commissioned by Molecular Cell, world leader in chromosome dynamics Tatsuya Hirano, of the Riken Advanced Science Institute in Japan, qualifies the research as a tour de force study that will help address outstanding questions in the field. Carolyne Lord University of Montreal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):